fda glp-1 compounding enforcement news Compounded weight-loss and hormone drugs are booming, but experts say regulators have little visibility into who is taking them or what side effects they may be causing. ⁠ ⁠ Critics warn that New project announcement: HHS‑OIG is

The effectiveness of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists on cardiorenal outcomes: systematic review and meta- analysis

Deeper into their supply chains, companies have also looked at changes to how products are packaged, stocked and replenished at the warehouse level

The medication and support provided make it easier for individuals to make and maintain these necessary lifestyle changes

But a recent review of the literature by researchers at the University of Virginia raised a flag: they found that while GLP-1 drug therapy clearly reduces body weight and fat, these benefits dont translate into significant improvements in VO2max or overall cardiorespiratory fitness (2)

Collet TH, Dubern B, Mokrosinski J, et al